Skip to main content

Table 3 OS and OS rate in high-risk and low-risk groups according to our model risk score in the training and validation cohort

From: A multi-parametric prognostic model based on clinical features and serological markers predicts overall survival in non-small cell lung cancer patients with chronic hepatitis B viral infection

Parameter Training cohort Validation cohort
High-risk group Low-risk group Total High-risk group Low-risk group Total
No. of patients 86 59 145 28 28 56
OS
 Median 15.0 63.0   12.5 59.0  
 IQR 7.0–40.0 38.0–74.0   7.25–21.50 33.50–72.25  
No. of OS
 At 1 year 51 (59.3%) 58 (98.1%) 109 (69.7%) 16 (57.1%) 25 (89.3%) 41 (73.2%)
 At 3 year 23 (26.7%) 45 (76.3%) 68 (46.9%) 4 (14.3%) 20 (71.4%) 24 (42.9%)
 At 5 year 10 (11.6%) 36 (61.0%) 46 (31.7%) 1 (3.6%) 14 (50.0%) 15 (26.8%)
  1. OS overall survival, IQR interquartile range